提高噬菌体裂解酶抗菌活性的研究进展

随着细菌耐药性问题的日益严重,人们开始寻求新型抗菌制剂。噬菌体裂解酶是一种由ds DNA噬菌体编码的水解酶,能高效特异性地裂解细菌细胞壁且不易使细菌产生耐药性。由于天然裂解酶具有宿主谱窄,不能裂解革兰阴性菌等缺点,研究者对裂解酶进行了大量的设计改造。本研究主要对提高噬菌体裂解酶抗菌活性的研究进展进行综述。     

噬菌体裂解酶——现状与未来

噬菌体裂解酶是一种由DNA噬菌体基因编码的高特异性酶, 可高效消化细菌细胞壁。革兰氏阳性菌噬菌体裂解酶的结构域相似, 裂解效率高, 与抗生素具协同抗菌作用, 且不易产生耐受性菌株, 抗体等体液因子对裂解酶的裂解活性影响小, 裂解酶作为一种潜在抗感染药物具有重要的研究价值。目前已建立了多种病原菌裂解酶应用的动物模型, 在防控耐药性病原菌感染上取得重要进展。本文就噬菌体裂解酶的抗菌作用进行综述。     

噬菌体裂解酶研究进展

噬菌体裂解酶是双链DNA噬菌体所特有的细胞壁水解酶。研究表明,所有噬菌体裂解酶在结构上具有相似性,即含有2个结构域：比较保守的N端催化区和差异较大的C端特异性结合区。裂解酶的高亲和性与种属特异的细胞壁糖基有关,而后常常是细菌存活的必要成分。所以,细菌难以产生对裂解酶的抗性。本简要综述噬茵体裂解酶的研究进展。     

裂解酶治疗的研究进展与应用前景

多耐药病原细菌的不断出现和传播给公共医疗造成了严峻的威胁和挑战,开发新的抗菌分子迫在眉睫。噬菌体裂解酶来源于噬菌体,具有独特的进化和选择优势,不仅能高效快速的杀灭多耐药细菌,而且不易诱导细菌产生新的耐药性。本文对噬菌体裂解酶的结构和功能进行了简要的介绍,重点综述了裂解酶在抗细菌感染中近年的研究进展和应用前景。     

噬菌体及其裂解酶控制金黄色葡萄球菌的研究进展

近70年来,由于抗生素的广泛使用,耐药金黄色葡萄球菌不断出现。美国1999～2005年因感染耐甲氧西林金黄色葡萄球菌（MRSA）而入院的患者增加1倍多,其中诊断为败血症的患者增加81．2％。因此,寻找控制耐药菌的新对策十分迫切。目前有望替代抗生素的控菌手段有抗菌肽、噬菌体等。其中,噬菌体的发现早于抗生素,后因抗生素的普及而被忽视。如今,耐药菌株的流行使噬菌体治疗再次受到关注。本文就应用噬菌体及其裂解酶控制金黄色葡萄球菌的研究进展进行综述。     

噬菌体裂解酶的抗菌特性

摘要：噬菌体裂解酶是一类细胞壁水解酶,可水解肽聚糖,造成细菌的破裂。裂解酶一般具有两到三个结构域,参与对底物的催化和结合。作为一种新型的杀菌制剂,裂解酶已被越来越多地应用于化脓链球菌、肺炎链球菌、金黄色葡萄球菌等革兰氏阳性细菌病的治疗。与抗生素治疗相比,裂解酶不易使细菌产生抗性且作用相对专一,这可能是解决现在日趋严重的细菌耐药性的一种可行方法。另外,裂解酶还具有高效性,作用协同性,且自身抗体不削弱其作用等优势,使之成为未来预防、控制致病菌一种可能的新途径。     

噬菌体及其裂解酶对细菌生物被膜作用的研究进展

细菌形成的生物被膜,可保护细菌不易被抗生素杀死,这给临床上相应疾病的治疗及医疗器械的消毒带来极大困难。研究表明,噬菌体及其裂解酶对生物被膜有降解作用。噬菌体能清除细菌在有生物活性或无生物活性的介质表面形成的生物被膜。此外,噬菌体裂解酶比如LySMP、肽酶CHAPk、细胞壁溶解酶CWHs等能清除特定的生物被膜,这可能与裂解酶直接溶菌和裂解细菌细胞外基质有关。同时,与抗生素、钴离子、氯等物质联合使用时,噬菌体对生物被膜的清除作用会更强。本文从噬菌体、噬菌体编码的裂解酶、以及它们联合其他物质对细菌生物被膜的作用进行综述,并对其实际应用做了展望。     

噬菌体及其裂解酶在食源性致病菌检测和控制中的应用

微生物致病菌引起的食源性疾病在全世界频频发生,对人类健康造成严重危害,尤其是致病菌耐药性的出现使常规治疗陷入困境。噬菌体及其编码的裂解酶的发现及应用,为食源性致病菌的检测及生物防治开辟了新的途径。综述噬菌体及其裂解酶在构建食源性致病菌的快速检测方法和生物防治方面的应用。     

炭疽杆菌噬菌体裂解酶基因在大肠杆菌中的表达及鉴定

利用PCR方法扩增炭疽杆菌噬菌体裂解酶 (γlysin)基因 ,克隆至大肠杆菌表达载体pET2 2b中 ,经菌落PCR筛选、序列测定和酶切鉴定证实表达载体pET22b-γlysin构建成功 ,并在EscherichiacoliBL21(DE3)中获得了高表达。目的蛋白约占菌体总蛋白的40% ,5L发酵罐中的产酶水平高达 15g L。菌体经超声破碎 ,制备无细胞抽提液 ,StreamlineSP和SPHP柱层析以及SephacrylS-100凝胶过滤三步纯化 ,得到分子量为 2 7kD单一条带的目的蛋白 ,薄层扫描分析显示其纯度大于 95 %。目的蛋白的收率为19.1% ,纯化倍数为350。生物活性鉴定重组的γ噬菌体裂解酶具有特异性 :可快速裂解炭疽杆菌 ,比活为 1400u mg左右 ;而对大肠杆菌、枯草杆菌及蜡样芽孢杆菌没有裂解活性。     

鱼源副乳房链球菌前噬菌体裂解酶Sply828的抗菌活性

【背景】副乳房链球菌（Streptococcus parauberis）是重要的水产病原菌,该病原菌已逐渐出现新的血清型及多重耐药性状,因此亟须开发出一种新的抗菌药物用于该病害的防治。研究发现,前噬菌体编码的裂解酶能够有效地杀死其宿主,具有良好的抗菌应用前景。【目的】以副乳房链球菌前噬菌体裂解酶为对象,研究其杀菌宿主谱并优化其裂解活性的条件。【方法】利用PHASTER工具对副乳房链球菌菌株KRS02083全基因组序列分析发现,其前噬菌体包含一种裂解酶的基因Sply828;通过基因克隆、表达和纯化等技术得到裂解酶Sply828蛋白;通过浊度递减实验探究裂解酶Sply828对不同细菌的杀菌活性及其最适的裂解条件。【结果】裂解酶Sply828对鱼源副乳房链球菌具有最佳的杀菌活性,并发现该酶对处于指数生长期的细菌杀菌效果最好;其最适裂解温度为28°C,最适pH为6.2;Ca²⁺和Mg²⁺对该酶的杀菌活性有促进作用,但是Zn²⁺、Cu²⁺、Fe²⁺、Ni²⁺明显抑制...     

Bacteriophage and their lysins for elimination of infectious bacteria

When phages were originally identified, the possibility of using them as antibacterial agents against pathogens was immediately recognized and put into practise based on the knowledge available at the time. However, with the advent of antibiotics a decline in the use of phage as therapeutics followed. Phages did, however, become more useful in the study of fundamental aspects of molecular biology and in the diagnostic laboratory for the identification of pathogenic bacteria. More recently, the original application of phage as therapeutics to treat human and animal infections has been rekindled, particularly in an era where antibiotic resistance has become so problematic/commonplace. Phage lysins have also been studied and utilized in their own right as potential therapeutics for the treatment of bacterial infections. Indeed the past decade has seen a considerable amount of research worldwide focused on the engineering of phages as antibacterial agents in a wide range of applications. Furthermore, the US Food and Drug Administration and/or the US Department of Agriculture have recently approved commercial phage preparations to prevent bacterial contamination of livestock, food crops, meat and other foods. Such developments have prompted this review into the status of phage research as it pertains to the control of infectious bacteria.     

Tail-associated structural protein gp61 of Staphylococcus aureus phage φMR11 has bifunctional lytic activity

A tailed bacteriophage, φMR11 (siphovirus), was selected as a candidate therapeutic phage against Staphylococcus aureus infections. Gene 61, one of the 67 ORFs identified, is located in the morphogenic module. The gene product (gp61) has lytic domains homologous to CHAP (corresponding to an amidase function) at its N-terminus and lysozyme subfamily 2 (LYZ2) at its C-terminus. Each domain of gp61 was purified as a recombinant protein. Both the amidase [amino acids (aa) 1–150] and the lysozyme (aa 401–624) domains but not the linker domain (aa 151–400) caused efficient lysis of S . aureus . Immunoelectron microscopy localized gp61 to the tail tip of the φMR11 phage. These data strongly suggest that gp61 is a tail-associated lytic factor involved in local cell-wall degradation, allowing the subsequent injection of φMR11 DNA into the host cytoplasm. Staphylococcus aureus lysogenized with φMR11 was also lysed by both proteins. Staphylococcus aureus strains on which φMR11 phage can only produce spots but not plaques were also lysed by each protein, indicating that gp61 may be involved in 'lysis from without'. This is the first report of the presence of a tail-associated virion protein that acts as a lysin, in an S. aureus phage.     

Genome sequence of Streptococcus mutans bacteriophage M102

Bacteriophage M102 is a lytic phage specific for serotype c strains of Streptococcus mutans, a causative agent of dental caries. In this study, the complete genome sequence of M102 was determined. The genome is 31,147 bp in size and contains 41 ORFs. Most of the ORFs encoding putative phage structural proteins show similarity to those from bacteriophages from Streptococcus thermophilus. Bioinformatic analysis indicated that the M102 genome contains an unusual lysis cassette, which encodes a holin and two lytic enzymes.     

猪链球菌的烈性噬菌体和前噬菌体

猪链球菌(Streptococcus suis,S.suis)是一种重要的人畜共患病病原,携带有前噬菌体。本文对猪链球菌的烈性噬菌体和前噬菌体的研究现状做了综述,主要包括猪链球菌烈性噬菌体的形态及功能;烈性噬菌体裂解酶的结构及功能;烈性噬菌体末端酶大亚基的活性;前噬菌体的比较基因组学、前噬菌体的裂解酶以及烈性噬菌体和溶原性噬菌体之间的相互转化,并对猪链球菌噬菌体与宿主的相互关系作了展望。     

链球菌噬菌体裂解酶在大肠杆菌中的表达、纯化及活性检测

噬菌体裂解酶是噬菌体产生的细胞壁水解酶,通过水解宿主菌细胞壁使子代噬菌体释放,在体外能高效且特异性地杀死细菌。本研究旨在克隆和表达链球菌噬菌体裂解酶PlyC,并测定其生物学活性。利用PCR方法扩增PlyC的2条肽链PlyCA和PlyCB,构建表达载体pET-32a(+)-PlyCA和pET-32a(+)-PlyCB,分别转化至大肠杆菌BL21(DE3)中,以0.7 mmol/L IPTG在30 oC诱导7 h实现了高效表达,SDS-PAGE分析表明PlyCA和PlyCB表达量均可达菌体总蛋白的30%以上。采用Ni2+-NTA亲和层析法纯化目的蛋白,其纯度大于95%。用透析复性方法得到目的产物重组链球菌噬菌体裂解酶PlyC,以浊度法和平板计数法检测其体外抗菌效果,扫描电子显微镜观察裂解酶作用前后细菌细胞形态变化。结果表明重组PlyC能特异性裂解化脓性链球菌(A组β-溶血性链球菌),以4μg/mL浓度作用于OD600为0.56的菌液60 min后杀菌率达99.6%,扫描电镜观察结果显示该酶作用于菌体后,链球菌细胞裂解,呈碎片状态。本研究为开发一种新型、高效的链球菌感染疾病治疗药物打下了基础。     

Complete genome sequence of a newly isolated lytic bacteriophage,EFAP‐1 of Enterococcus faecalis,and antibacterial activity of its endolysin EFAL‐1

Aims: In this work, we aimed to identify an effective treatment of infections caused by Enterococcus spp. strains resistant to conventional antibiotics. Methods and Results: We report the isolation and characterization of a new lytic bacteriophage, designated bacteriophage EFAP‐1, that is capable of lysing Enterococcus faecalis bacteria that exhibit resistance to multiple antibiotics. EFAP‐1 has low sequence similarity to all known bacteriophages. Transmission electron microscopy confirmed that EFAP‐1 belongs to the Siphoviridae family. A putative lytic protein of EFAP‐1, endolysin EFAL‐1, is encoded in ORF 2 and was expressed in Escherichia coli. Recombinant EFAL‐1 had broad‐spectrum lytic activity against several Gram‐positive pathogens, including Ent. faecalis and Enterococcus faecium. Conclusions: The complete genome sequence of the newly isolated enterococcal lytic phage was analysed, and it was demonstrated that its recombinant endolysin had broad lytic activity against various Gram‐positive pathogens. Significance and Impact of the Study: Bacteriophage EFAP‐1 and its lytic protein, EFAL‐1, can be utilized as potent antimicrobial agents against Enterococcus spp. strains resistant to conventional antibiotics in hospital infections and also as environmental disinfectants to control disease‐causing Enterococcus spp. in dairy farms.     

Genetically engineered phage harbouring the lethal catabolite gene activator protein gene with an inducer-independent promoter for biocontrol of Escherichia coli

Complications of chemotherapy, such as appearance of multidrug resistance, have persuaded researchers to consider phage therapy as a new method to combat bacterial infections. In vitro experiments were performed to assess the therapeutic value of genetically modified phages for controlling gastrointestinal Escherichia coli O157:H7 cells in Luria–Bertani (LB) media and contaminated cow milk. We constructed a modified nonreplicating M13-derived phage expressing a lethal catabolite gene activator protein (CAP) that is a Glu181Gln mutant of CAP. The modified phagemid was propagated in the lethal CAP-resistant strain XA3DII. Time–kill assay experiments showed a considerable reduction in the number of surviving bacteria in both LB media and contaminated cow milk. Our further study using other test strains demonstrated that the host range of lethal phage is limited to E. coli strains that produce pili. This study provides a possible strategy for the exploitation of genetically engineered nonlytic phages as bactericidal agents by minimizing the risk of release of progeny phages and endotoxins into the environment. The phage was engineered to remain lethal to its bacterial target, but incapable of replicating therein. Furthermore, the addition of an inducer to express the lethal protein is not required.